Organigram (US:OGI) Financial Modeling Prep·2025-12-17 01:04Core Insights - Organigram Holdings Inc. is a significant player in the Canadian cannabis industry, focusing on recreational cannabis products [1] - Alliance Global Partners has a "Buy" rating for Organigram, raising the price target from C$3.60 to C$4, reflecting confidence in the company's future performance [1][5] Financial Performance - Organigram reported a quarterly loss of C$(0.283) per share, which is significantly below the Zacks Consensus Estimate and represents a substantial increase from the $0.04 loss per share reported in the same quarter last year [2][5] - The company's revenue for the quarter ending September 2025 was C$80.1 million, exceeding the Zacks Consensus Estimate by 7.1%, indicating strong sales growth despite earnings challenges [3][5] Stock Performance - Organigram's stock is currently priced at $1.93, reflecting a positive change of 7.5% or an increase of $0.135, with a trading volume of 3,754,420 shares [4] - The stock has fluctuated between a low of $1.70 and a high of $1.98 during the day, and over the past year, it has reached a high of $2.07 and a low of $0.85 [4]